RIAS
ARQT icon

Rachor Investment Advisory Services’s Arcutis Biotherapeutics ARQT Stock Holding History

Rachor Investment Advisory Services’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-269
Closed -$6.34K – 225
2026
Q1 		$6.34K Sell
269
-6
-2% -$153 ﹤0.01% 146
2025
Q4 		$7.99K Buy
+275
New +$7.04K ﹤0.01% 125

Other funds holding ARQT

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
PL
Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
JAFL
Jay A. Fishman Ltd Troy, Michigan $1.26B AUM 31.39% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Rachor Investment Advisory Services's ARQT Position: Q2 2026 in Review

Rachor Investment Advisory Services sold out of Arcutis Biotherapeutics (ARQT) in Q2 2026, closing a stake of 269 shares — an estimated $6.34K sold.

Rachor Investment Advisory Services first reported a position in ARQT in Q4 2025 and held it in 2 quarters. The position peaked at $7.99K in Q4 2025. 72 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Rachor Investment Advisory Services reported no remaining Arcutis Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • Rachor Investment Advisory Services sold 269 Arcutis Biotherapeutics shares in Q2 2026, an estimated $6.34K.
  • Rachor Investment Advisory Services first reported a position in Arcutis Biotherapeutics in Q4 2025 and held it in 2 quarters.
  • Rachor Investment Advisory Services's Arcutis Biotherapeutics position peaked at $7.99K in Q4 2025.
  • 72 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Rachor Investment Advisory Services's 13F filing for Q2 2026, filed 16 Jul 2026.